Renalytix plc (RENX) ORD GBP0.0025
Renalytix plc, formerly Renalytix AI plc, is an artificial intelligence-enabled in vitro diagnostics company. The Company's diagnostic platform, KidneyIntelX, employs artificial intelligence-enabled algorithm that combines data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (HER) systems, to generate a patient risk score. Its patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians and healthcare systems to manage the allocation of treatments and clinical resources to patients. KidneyIntelX provides a reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to manage patient treatment and compliance outcomes. The KidneyIntelX risk score is tied to specific clinical guideline recommendations developed by the healthcare system, health insurance providers or practice groups.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.